About the company
Alnylam Pharmaceuticals has emerged as a global leader in the field of RNA interference (RNAi) therapeutics, harnessing the potential of this groundbreaking biological pathway to develop innovative and effective treatments for a wide range of medical conditions. RNA interference is a natural mechanism found in cells that allows for the precise regulation and silencing of specific genes. By utilizing this pathway, Alnylam is able to develop therapeutics that target disease-causing genes with remarkable precision, opening up new possibilities for treating previously untreatable conditions. One of Alnylam's notable achievements is the successful development and commercialization of five drugs on the market. Onpattro and Amvuttra are breakthrough treatments for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), a rare and debilitating disease caused by the buildup of amyloid proteins in various organs. These drugs have shown remarkable efficacy in slowing down the progression of the disease and improving patients' quality of life. Another remarkable achievement is Givlaari, a treatment for acute hepatic porphyria, a group of rare genetic disorders that affect the production of heme, an essential component of hemoglobin. Givlaari has demonstrated unprecedented efficacy in reducing the frequency and severity of attacks in patients, offering hope to those who have long suffered from this debilitating condition. Alnylam's portfolio also includes Oxlumo, the first-ever approved therapy for primary hyperoxaluria type 1 (PH1), a rare genetic disorder that causes the overproduction of oxalate, leading to the formation of kidney stones and organ damage. Oxlumo has shown significant promise in reducing the levels of oxalate in patients and preventing the progression of the disease. In addition to these breakthrough drugs, Alnylam has several clinical programs underway in various therapeutic areas. The company is actively researching and developing genetic medicines that have the potential to revolutionize the treatment of genetic disorders, providing hope to patients and families affected by these conditions. Alnylam is also focusing on cardio-metabolic diseases, recognizing the increasing burden of conditions such as cardiovascular disease and diabetes in global healthcare. By leveraging RNAi therapeutics, the company aims to develop innovative therapies that can effectively manage these diseases and improve patient outcomes. Furthermore, Alnylam is dedicated to addressing hepatic infectious diseases, such as hepatitis B and C, utilizing its RNAi platform to target the viral genes responsible for these infections. These efforts hold great promise for developing effective treatments that can significantly improve the lives of patients affected by these chronic conditions. Lastly, Alnylam is expanding its research into central nervous system (CNS) and ocular diseases, recognizing the significant unmet needs in these areas. By targeting specific genes and pathways associated with conditions such as Alzheimer's disease, Parkinson's disease, and ocular disorders, Alnylam aims to develop therapies that can slow down disease progression and improve patients' quality of life. To support its research and development efforts, Alnylam has formed strategic partnerships and collaborations with leading academic institutions and pharmaceutical companies. These collaborations not only provide valuable resources and expertise but also generate upfront fees, milestone payments, and royalties, further bolstering the company's financial standing and ensuring continued growth and innovation. With its pioneering work in RNAi therapeutics, Alnylam Pharmaceuticals is poised to revolutionize the treatment landscape for numerous medical conditions, offering hope and improved outcomes to patients worldwide. As the company continues to advance its clinical programs and forge new partnerships, the future holds tremendous potential for the development of safe, effective, and transformative RNAi therapies.
Website: https://www.alnylam.com
Data updated: April 30, 2026
